Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | KDR | P35968 | 8/20 | 0.40 |
| ▸ | BRAF | P15056 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4448040 | 1.00 | KMT2A (0.43) | KMT2AKDRBRAFMEN1TSHR | |
| SCHEMBL1823180 | 0.94 | KMT2A (0.43) | KMT2AKDRMEN1TSHRKDM4E | |
| SCHEMBL1822975 | 0.94 | KMT2A (0.43) | KMT2AKDRMEN1TSHRKDM4E | |
| SCHEMBL4448045 | 0.91 | KMT2A (0.42) | KMT2AKDRBRAFMEN1TSHR | |
| SCHEMBL1822942 | 0.91 | KMT2A (0.51) | KMT2AMEN1KDM4EHSD17B10LMNA | |
| SCHEMBL1822945 | 0.91 | KMT2A (0.51) | KMT2AMEN1KDM4EHSD17B10LMNA | |
| SCHEMBL1825545 | 0.89 | KMT2A (0.43) | KMT2AMEN1TSHRKDM4EHSD17B10 | |
| SCHEMBL1823194 | 0.89 | KMT2A (0.43) | KMT2AMEN1TSHRKDM4EHSD17B10 | |
| SCHEMBL1823816 | 0.88 | KMT2A (0.44) | KMT2AKDRBRAFKDM4EHSD17B10 | |
| SCHEMBL1823818 | 0.88 | KMT2A (0.44) | KMT2AKDRBRAFKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118051-A1 | NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | Chelsea Therapeutics, Inc. (US) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008097180-A1 | NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | CHELSEA THERAPEUTICS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |